{"id":"https://openalex.org/W3083178856","doi":"https://doi.org/10.1158/1538-7445.am2020-2894","title":"Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma","display_name":"Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma","publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3083178856","doi":"https://doi.org/10.1158/1538-7445.am2020-2894","mag":"3083178856"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-2894","doi":"https://doi.org/10.1158/1538-7445.am2020-2894","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-2894","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063142962","display_name":"Shawn P. Fessler","orcid":"https://orcid.org/0000-0003-4027-5490","observed_orcids":["https://orcid.org/0000-0003-4027-5490"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shawn Fessler","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087527292","display_name":"Anouk Dirksen","orcid":"https://orcid.org/0000-0002-7299-8696","observed_orcids":["https://orcid.org/0000-0002-7299-8696"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anouk Dirksen","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065815396","display_name":"Scott D. Collins","orcid":"https://orcid.org/0009-0008-6068-4623","observed_orcids":["https://orcid.org/0009-0008-6068-4623"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott D. Collins","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077581333","display_name":"Ling Xu","orcid":"https://orcid.org/0000-0002-9236-3014","observed_orcids":["https://orcid.org/0000-0002-9236-3014"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ling Xu","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038640727","display_name":"Winnie Lee","orcid":"https://orcid.org/0000-0001-6126-4841","observed_orcids":["https://orcid.org/0000-0001-6126-4841"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Winnie Lee","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jason Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Wang","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011177701","display_name":"Ronald S. Eydelloth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ron Eydelloth","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020791417","display_name":"Elena Ter\u2010Ovanesyan","orcid":"https://orcid.org/0000-0003-3018-9193","observed_orcids":["https://orcid.org/0000-0003-3018-9193","https://orcid.org/0009-0006-5204-7849"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elena Ter-Ovanesyen","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042117966","display_name":"Jeffrey Zurita","orcid":"https://orcid.org/0009-0009-1054-5358","observed_orcids":["https://orcid.org/0009-0009-1054-5358"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Zurita","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004874890","display_name":"Elizabeth Ditty","orcid":"https://orcid.org/0009-0004-4605-5880","observed_orcids":["https://orcid.org/0009-0004-4605-5880"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Ditty","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108771789","display_name":"Barrett J. Nehilla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barrett Nehilla","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015303673","display_name":"Susan M. Clardy","orcid":"https://orcid.org/0000-0002-0525-8903","observed_orcids":["https://orcid.org/0000-0002-0525-8903"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Clardy","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015303673","display_name":"Susan M. Clardy","orcid":"https://orcid.org/0000-0002-0525-8903","observed_orcids":["https://orcid.org/0000-0002-0525-8903"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Clardy","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048490905","display_name":"Tyler Carter","orcid":"https://orcid.org/0009-0003-1932-5884","observed_orcids":["https://orcid.org/0009-0003-1932-5884"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tyler Carter","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031978777","display_name":"Kenneth Avocetien","orcid":"https://orcid.org/0009-0006-7808-682X","observed_orcids":["https://orcid.org/0009-0006-7808-682X"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Avocetien","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074919843","display_name":"Mark Nazzaro","orcid":"https://orcid.org/0009-0000-5411-8176","observed_orcids":["https://orcid.org/0009-0000-5411-8176"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Nazzaro","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022927308","display_name":"Nam Le","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nam Le","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021812705","display_name":"Kalli C. Catcott","orcid":"https://orcid.org/0000-0003-1941-0678","observed_orcids":["https://orcid.org/0000-0003-1941-0678"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kalli C. Catcott","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055577586","display_name":"Alex Uttard","orcid":"https://orcid.org/0009-0006-1246-9756","observed_orcids":["https://orcid.org/0009-0006-1246-9756"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alex Uttard","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014070960","display_name":"Bingfan Du","orcid":"https://orcid.org/0009-0006-1276-2303","observed_orcids":["https://orcid.org/0009-0006-1276-2303"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bingfan Du","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030588596","display_name":"Chen\u2010Ni Chin","orcid":"https://orcid.org/0009-0002-1304-8161","observed_orcids":["https://orcid.org/0009-0002-1304-8161"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chen-Ni Chin","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022996406","display_name":"Rebecca E. Mosher","orcid":"https://orcid.org/0009-0005-8790-6247","observed_orcids":["https://orcid.org/0009-0005-8790-6247"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Mosher","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030056081","display_name":"Kelly L. Slocum","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly Slocum","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047322372","display_name":"LiuLiang Qin","orcid":"https://orcid.org/0009-0006-4855-1604","observed_orcids":["https://orcid.org/0009-0006-4855-1604"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liuliang Qin","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078721181","display_name":"David H. Lee","orcid":"https://orcid.org/0000-0002-5662-4010","observed_orcids":["https://orcid.org/0000-0002-5662-4010"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Lee","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078687678","display_name":"Dorin Toader","orcid":"https://orcid.org/0000-0001-6330-5280","observed_orcids":["https://orcid.org/0000-0001-6330-5280"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dorin Toader","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007306710","display_name":"Marc Isaac Damelin","orcid":"https://orcid.org/0000-0003-0512-7126","observed_orcids":["https://orcid.org/0000-0003-0512-7126"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc Damelin","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080692466","display_name":"Timothy B. Lowinger","orcid":"https://orcid.org/0000-0002-4209-3693","observed_orcids":["https://orcid.org/0000-0002-4209-3693"]},"institutions":[{"id":"https://openalex.org/I4210164288","display_name":"Mersana Therapeutics (United States)","ror":"https://ror.org/05jyg6z06","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164288"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy B. Lowinger","raw_affiliation_strings":["Mersana Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mersana Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164288"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210164288"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"2894","last_page":"2894"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.7710000276565552,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.7710000276565552,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.04019999876618385,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.027699999511241913,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8629999756813049},{"id":"https://openalex.org/keywords/napi2b","display_name":"NaPi2b","score":0.9449999928474426},{"id":"https://openalex.org/keywords/slc34a2","display_name":"SLC34A2","score":0.9940000176429749},{"id":"https://openalex.org/keywords/site-specific-conjugation","display_name":"site-specific conjugation","score":0.906000018119812},{"id":"https://openalex.org/keywords/drug-to-antibody-ratio","display_name":"drug-to-antibody ratio","score":0.921999990940094},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.9430000185966492},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.996999979019165},{"id":"https://openalex.org/keywords/targeted-cancer-therapy","display_name":"targeted cancer therapy","score":0.5839999914169312},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8830000162124634},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.8259999752044678}],"concepts":[{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.648423969745636},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6042212843894958},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.5387270450592041},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5096049308776855},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4717441499233246},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.37053853273391724},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2358514666557312},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.14793053269386292},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-2894","doi":"https://doi.org/10.1158/1538-7445.am2020-2894","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-2894","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4392632857","https://openalex.org/W2487451536","https://openalex.org/W4409626642","https://openalex.org/W3138613607","https://openalex.org/W2136344029","https://openalex.org/W2885864185","https://openalex.org/W3028768661","https://openalex.org/W4256385799","https://openalex.org/W2570018616","https://openalex.org/W7148740567"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"Dolasynthen":[2],"platform":[3],"incorporates":[4],"the":[5,24,34,99,160,165,184,207,235,309,321,325],"highly":[6],"potent":[7,128,141],"anti-mitotic":[8],"agent":[9],"auristatin":[10],"F-HPA":[11],"(AF-HPA),":[12],"with":[13,30,117,159],"its":[14,221],"associated":[15],"DolaLock":[16],"mechanism":[17],"of":[18,26,33,47,105,115,164,174,186,189,199,206,237,311,320,324],"controlled":[19],"bystander":[20],"effect,":[21],"and":[22,38,51,85,101,129,142,171,195,216,314,335],"enables":[23],"synthesis":[25],"antibody-drug":[27,306],"conjugates":[28],"(ADCs)":[29],"precise":[31],"control":[32],"drug-to-antibody":[35],"ratio":[36],"(DAR)":[37],"site-specific":[39,56,187,303],"bioconjugation.":[40],"XMT-1592":[41,116,126,139,168,200,209,229],"is":[42,67,73,96],"a":[43,55,68,111,202,231,302],"novel":[44],"ADC":[45,166],"comprised":[46],"an":[48],"anti-NaPi2b":[49],"antibody":[50],"Dolasynthen,":[52,190],"conjugated":[53,124,204],"in":[54,79,98,131,144,147,193,196,212],"manner":[57],"to":[58,176,201,220],"yield":[59],"DAR":[60],"6.":[61],"NaPi2b,":[62],"also":[63],"known":[64],"as":[65,230],"SLC34A2,":[66],"transmembrane":[69],"sodium-phosphate":[70],"transporter":[71],"that":[72,93,119],"broadly":[74],"expressed":[75],"on":[76],"tumor":[77,87,149],"cells":[78],"ovarian":[80,136,153,312],"carcinoma,":[81],"NSCLC":[82],"lung":[83,106,156,315],"adenocarcinoma":[84,316],"other":[86],"types.":[88],"Recent":[89],"studies":[90,109],"have":[91],"shown":[92],"NaPi2b":[94,118],"expression":[95],"enriched":[97],"EGFR":[100],"KRAS":[102],"mutant":[103],"subtypes":[104],"adenocarcinoma.":[107,157],"Binding":[108],"showed":[110],"specific,":[112],"high-affinity":[113],"interaction":[114],"was":[120],"not":[121,179],"affected":[122],"by":[123],"Dolasynthen.":[125],"elicited":[127],"specific":[130,143],"vitro":[132,194],"cytotoxicity":[133],"against":[134],"NaPi2b-expressing":[135,148,238],"carcinoma":[137,154],"cells.":[138],"exhibited":[140],"vivo":[145,197,213],"activity":[146],"xenografts":[150],"derived":[151],"from":[152],"or":[155],"Consistent":[158],"targeted":[161],"delivery":[162],"benefits":[163,185],"approach,":[167],"yielded":[169],"high":[170],"sustained":[172],"concentrations":[173],"AF-HPA":[175],"tumors":[177],"but":[178],"normal":[180],"tissues.":[181],"To":[182],"evaluate":[183],"bioconjugation":[188],"we":[191],"conducted":[192],"comparisons":[198],"stochastically":[203],"version":[205],"ADC.":[208],"had":[210],"improved":[211],"activity,":[214],"pharmacokinetics,":[215],"clinical":[217],"pathology":[218],"relative":[219],"stochastic":[222],"counterpart.":[223],"Taken":[224],"together,":[225],"these":[226],"results":[227],"support":[228],"development":[232],"candidate":[233],"for":[234,308,328],"treatment":[236,310],"tumors.":[239],"Citation":[240],"Format:":[241],"Shawn":[242],"Fessler,":[243],"Anouk":[244],"Dirksen,":[245],"Scott":[246],"D.":[247],"Collins,":[248],"Ling":[249],"Xu,":[250],"Winnie":[251],"Lee,":[252,293],"Jason":[253],"Wang,":[254],"Ron":[255],"Eydelloth,":[256],"Elena":[257],"Ter-Ovanesyen,":[258],"Jeffrey":[259],"Zurita,":[260],"Elizabeth":[261],"Ditty,":[262],"Barrett":[263],"Nehilla,":[264],"Susan":[265,267],"Clardy,":[266,268],"Tyler":[269],"Carter,":[270],"Kenneth":[271],"Avocetien,":[272],"Mark":[273],"Nazzaro,":[274],"Nam":[275],"Le,":[276],"Kalli":[277],"C.":[278],"Catcott,":[279],"Alex":[280],"Uttard,":[281],"Bingfan":[282],"Du,":[283],"Chen-Ni":[284],"Chin,":[285],"Rebecca":[286],"Mosher,":[287],"Kelly":[288],"Slocum,":[289],"Liuliang":[290],"Qin,":[291],"David":[292],"Dorin":[294],"Toader,":[295],"Marc":[296],"Damelin,":[297],"Timothy":[298],"B.":[299],"Lowinger.":[300],"XMT-1592,":[301],"Dolasynthen-based":[304],"NaPi2b-targeted":[305],"conjugate":[307],"cancer":[313],"[abstract].":[317],"In:":[318],"Proceedings":[319],"Annual":[322],"Meeting":[323],"American":[326],"Association":[327],"Cancer":[329,341],"Research":[330],"2020;":[331],"2020":[332],"Apr":[333],"27-28":[334],"Jun":[336],"22-24.":[337],"Philadelphia":[338],"(PA):":[339],"AACR;":[340],"Res":[342],"2020;80(16":[343],"Suppl):Abstract":[344],"nr":[345],"2894.":[346]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2020-09-11T00:00:00"}